Clinical Trial Update: Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating radiation in combination with BCMA/CD3 bispecific antibody therapy for solitary bone plasmacytoma with mild bone marrow infilt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasma Cell Disorders
• Plasmacytoma of Bone
• Solitary Bone Plasmacytoma

Drugs mentioned

• BCMA/CD3 bispecific antibody therapy

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Solitary Bone Plasmacytoma, Plasmacytoma of Bone | Phase 2 | Status: RECRUITING